13 Sep 2018

Top Pharma & Biotech Deals, Investments, M&As in August 2018

In August, the biotech boom of 2018 continued unabated and the Wall Street Journal reported that investment banks have lured top biotech analysts with guaranteed pay packages of US$ 3 million or more. At this time of the yea...

Radio Compass

PharmaCompass.com

13 Sep 2018

Sun, Dr. Reddy’s rework strategies to deal with US market; Novartis sells troubled US biz to Aurobindo

This week, Phispers has news on Indian generic drug makers. First, Sun Pharma and Dr. Reddy’s Laboratories announced their reworked strategies that are driven by severe pressures in the US market. While DRL plans to double i...

Radio Compass

PharmaCompass.com

06 Sep 2018

Novartis plans job cuts in Switzerland; Researcher pleads guilty of stealing GSK’s trade secrets

This week, Phispers brings you details of the scam at GSK, wherein a former cancer researcher in the US stole trade secrets for the benefit of the companies she had started. Seven months ahead of the Brexit, Britain begins to f...

Radio Compass

PharmaCompass.com

30 Aug 2018

Data integrity concerns in Japan at Kyowa Hakko; China biotech plant explosion probe

This week, Phispers brings you news on Kyowa Hakko, a Japanese manufacturer of amino acids, which received an FDA warning letter with a recommendation to implement data integrity remediation measures. There is also news on tech bi...

Radio Compass

PharmaCompass.com

23 Aug 2018

FDA, EMA highlight more concerns over APIs from China; FDA slams Apotex’s India operations

This week, Phispers brings you more news on quality problems with active pharmaceutical ingredients from China. The FDA commissioner,  through a series of tweets and press statements, announced that the US regulatory agency i...

Radio Compass

PharmaCompass.com

16 Aug 2018

Top Pharma & Biotech Deals, Investments, M&As – July 2018

July may not have seen any big-ticket deals — i.e. deals in excess of US$ 1 billion — in the pharma and biotech space. Yet, deal making remained robust last month as well. Companies like Novartis, Roche, Lilly ...

Radio Compass

PharmaCompass.com

16 Aug 2018

Headwinds at Mylan; Chinese API Adulteration Concerns Trigger Another US Drug Recall

This week in Phispers, we look at Mylan’s US operations that declined 22 percent due to lower volumes. Moreover, quality concerns and supply chain tactics led to more headwinds at the American drug major. Two Form 483s redac...

Radio Compass

PharmaCompass.com

09 Aug 2018

High-level exit at Dr. Reddy’s; Drug stockpiling starts as firms face ‘no-deal Brexit’ blues

With Britain preparing for a ‘no-deal Brexit’, Phispers this week looks at how pharmaceutical companies are exploring various options, such as stockpiling, to equip themselves for such a scenario. In M&A news,...

Radio Compass

PharmaCompass.com

02 Aug 2018

FDA releases GDUFA II fee for FY19; AstraZeneca probed on bribes to Iraqi terrorists

This week, Phispers brings you the FY19 user fee schedule under GDUFA II, released by the USFDA, which saw a significant hike for generic drug applicants. For the first time since its launch in 2014, Merck’s Keytruda beat Br...

Radio Compass

PharmaCompass.com

30 Jul 2018

Kemiex reduces the risk of payment redirection frauds for pharma industry

The pharmaceutical industry is facing a daunting challenge of financial frauds where payments due to suppliers are getting re-directed to criminal bank accounts. This week, PharmaCompass speaks to Pau Franquet, CEO...

Radio Compass

PharmaCompass.com

PharmaCompass >>